Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Moody's Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Moody's Corporation trades at $485.1 (market cap $87.42B). The key difference: Moody's Corporation is far larger — about 19.5× ACADIA Pharmaceuticals Inc.'s market cap, and Moody's Corporation pays a 0.82% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MCO | |
|---|---|---|
Market Cap | $4.49B | $87.42B |
Sector | Health | Financials |
52-Week High | $28.06 | $539.61 |
52-Week Low | $20.06 | $412.23 |
Enterprise Value | $3.69B | $93.23B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Moody's Corporation (MCO) trades at $500.49, up 2.03% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while trading at premium valuations (P/E 35.78). Recent AI integration announcements and dividend payments highlight strategic growth initiatives.
MCO presents a compelling growth story with strong profitability and analyst support (56% buy ratings, $542 consensus target), though elevated valuations and RSI overbought signals warrant caution. Key risks include competitive pressures and market sensitivity to credit cycles, but the company's market position and AI strategy support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
